BlackRock Portfolio Management LLC filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 3,587,013 shares of Vanda Pharmaceuticals Inc. common stock, representing 5.9% of the class, as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported beneficial ownership of 3,587,013 shares of Vanda Pharmaceuticals Inc. common stock.
  • Percent of class: The reported position represents 5.9% of the outstanding common shares, according to the filing.
  • Sole voting power: The filing reports sole voting power over 3,228,683 shares, with no shared voting power.
  • Sole dispositive power: BlackRock Portfolio Management LLC reported sole dispositive power over the full 3,587,013 shares, with no shared dispositive power.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026.
  • Ordinary course certification: The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

BlackRock Portfolio Management's Schedule 13G Filing for Vanda Pharmaceuticals Common Stock

BlackRock Portfolio Management LLC, a Delaware-organized entity with a principal business address at 50 Hudson Yards, New York, NY 10001, filed a Schedule 13G disclosing a position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) common stock (CUSIP 921659108). The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, and reflects holdings as of the triggering event date of September 30, 2026.

According to the filing, BlackRock Portfolio Management LLC reported aggregate beneficial ownership of 3,587,013 shares, equal to 5.9% of the class. Of those shares, the filing indicates sole voting power over 3,228,683 shares and sole dispositive power over all 3,587,013 shares. Both shared voting power and shared dispositive power are reported as zero. The filing notes that it "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and explicitly states that it does not include securities, if any, beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units.

Regarding dividends or proceeds from sales, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Vanda Pharmaceuticals Inc." and that no single person's interest in the common stock exceeds five percent of the total outstanding common shares. The issuer, Vanda Pharmaceuticals Inc., is identified as having principal executive offices at 2200 Pennsylvania Ave NW, Suite 300E, Washington, DC 20037. The filing references Exhibit 99 for the identification of the relevant subsidiary that acquired the reported securities.

What Was Disclosed

BlackRock Portfolio Management LLC filed a Schedule 13G disclosing beneficial ownership of 3,587,013 shares, or 5.9%, of Vanda Pharmaceuticals Inc. common stock as of September 30, 2026, with sole voting power over 3,228,683 shares and sole dispositive power over all reported shares.